IGMPI Approvals & Accreditation : Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India, Approved Training Institute of Food Safety and Standards Authority of India (FSSAI), Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India, An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh, Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC)
Trusted by organizations & training participants in over 30 countries. Training | Certification | Education | Research

Experimental novel rheumatoid arthritis drug successful in final Phase of Clinical Trials

24th July 2019

A novel experimental drug is demonstrating encouraging results through its final phase of human clinical trials. Filgotinib is a JAK inhibitor selectively targeting the JAK1 enzyme. It is chiefly being investigated for the rheumatoid arthritis treatment, but initial clinical trials have encouraged for treatment of ulcerative colitis and Crohn's disease.

After years of development, scientists are going to publish some of the first observations from the final Phase 3 human trials into the new drug efficacy, ahead of an FDA application for moving the drug to market by 2020.

Principle investigator on clinical trial study suggested that these results are way better than any of the current first-generation JAK inhibitors which are already available clinically. He also observes that the new drug seems effective regardless of any other treatments a patient had previously undergone and failed.

This is unlike any of the traditional biological treatments for rheumatoid arthritis where subsequent therapies are rarely as valuable and efficacious as the first therapy a patient is being administered on.

For further enquiries, write to or call us on:
info@igmpiindia.org/ +91 8587838177, +91 8130924488, 0120-2427175, 0120-4375280

Pharmaceuticals | Food | Clinical Research | Healthcare | Medical Coding | Medical Device | Nanotechnology | IPR

Clinical Research Newsletter

Featured Article

GMP: A continous process

Mr Vinod Arora, Principal Advisor, IGMPI

IGMPI Placement Blog

Placement Testimonials

Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like